The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10584 malaria professionals are enjoying the free benefits of MalariaWorld today

mucosal priming

NOT Open Access | Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming

January 20, 2020 - 16:42 -- NOT Open Access
Author(s): 
McEntee CP, Moran HBT, Muñoz-Wolf N, Liddicoat AM, Carroll EC, Erbo-Wern J, Coulter IS, Andersen P, Follmann F, Lavelle EC.
Reference: 
Vaccine, Volume 38, Issue 3, 16 January 2020, Pages 635-643

Despite being in the midst of a global pandemic of infections caused by the pathogen Chlamydia trachomatis, a vaccine capable of inducing protective immunity remains elusive. Given the C. trachomatis mucosal port of entry, a formulation compatible with mucosal administration and capable of eliciting potent genital tract immunity is highly desirable. While subunit vaccines are considered safer and better tolerated, these are typically poorly immunogenic and require co-formulation with immune-potentiating adjuvants.

Subscribe to RSS - mucosal priming